KAYRROS
Kayrros SAS, a leading global asset observation platform, is today announcing the latest findings from its technology to track, quantify and attribute global methane emissions. Kayrros uses data from the European Space Agency (ESA) Copernicus program’s Sentinel-5 Precursor satellite and has built a detection and quantification model to trace emissions back to their source. These unique and comprehensive findings show that:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200330005801/en/
- Methane emissions can now be detected and quantified at an asset level on a global scale , which represents a major step-change in the ability to work towards the reduction of man-made emissions.
- The data shows that there are around 100 high volume-emitting events at any one time around the world. Together, in the course of one year, they are releasing 20 megatons of methane which is equivalent to 1.8 gigatons of CO2 in the first twenty years .1
- Through its proprietary attribution model, Kayrros can identify that around one half of that CO2 equivalent in the first twenty years, or 1 gigaton, are in regions with heavy industry such as oil & gas, coal mining, etc . This is equivalent to the total annual CO2 emissions of Germany and France together.2
Kayrros is a leading Earth observation analytics player able to combine extensive mapping of assets, deep sectoral understanding, and complex machine learning algorithms as well as detection and quantification models in order to identify the missing link between concentrations and emissions.
“What we are announcing today is ground-breaking,” says Antoine Rostand, CEO of Kayrros. “The combination of Sentinel 5-P satellite imagery and Kayrros technology represents a world first in the ability to track and attribute these substantial individual methane leaks. The good news is most of these are man-made and can easily be addressed through action by individual companies, governments and regulators.”
Claus Zehner, Sentinel 5-P Mission manager at ESA, says, “We are pleased to support Kayrros in its use of the Sentinel 5-P data to develop new tools for global methane emissions monitoring. Europe’s investment into satellite technology is ever more crucial if it can support the reduction of global emissions and slow down climate change.”
Kayrros has presented its methodology and approach to the European Commission and its Directorate General for Energy. The upcoming European strategy to reduce methane emissions will include a methodology for methane measurement and quantification that builds on Copernicus and other satellite data for detection and validation. Kayrros remains in dialogue with the European Commission about its work.
Kayrros has also worked with LSCE 3 scientists on Sentinel 5-P imagery to identify and quantify thousands of major methane plumes from various sources around the world. Thomas Lauvaux from the LSCE comments, “To date, only a handful of these large anthropogenic sources have been documented. To expand this, as Kayrros technology does, constitutes a significant step toward mitigating methane emissions around the globe, a significant contributor to climate change, with the support of operators who now have the required information to take immediate action.”
Antoine Rostand emphasizes, “The consequences of these findings are immense, as they enable individual companies in the energy sector to identify and address methane leaks across their networks. Equally, governments and regulators should take note that access to such detailed emissions data will drastically change their ability to hold emitters accountable and potentially reverse the trend of ever-increasing emissions rates.”
This technology is now available to the industry for immediate implementation.
About Kayrros
Kayrros is the leading global asset observation platform worldwide. Harnessing satellite imagery and unconventional data with machine learning, natural language processing and advanced mathematics, Kayrros delivers focused monitoring and measurement of energy and natural resource activity around the world. With access to data on more than 200,000 industry assets, Kayrros customers can observe individual or multiple assets in proprietary or multi-client workflows to analyse industrial and environmental performance for the insight needed to make optimal operational and financial decisions. For more information, please visit www.kayrros.com .
1 |
1 ton of methane is equivalent to 84 tons of CO2 in the first 20 years (Environment Defense Fund ). |
|
2 |
Based on World bank Databank on CO2 emissions for 2014 |
|
3 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200330005801/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
